Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
Remegen
company
About
Remegen is a biotech company focused on discovering and developing a new generation of targeted therapies for the treatments of cancer.
- 11 - 50
Details
- Last Funding Type
- Private Equity（PE）
- Industries
- Biotechnology,Health Care,Therapeutics
- Founded date
- Jan 1, 2008
- Number Of Employee
- 11 - 50
- Operating Status
- Active
RemeGen, Ltd. ("RemeGen") is a biopharmaceutical company in China dedicated to fulfilling unmet medical needs for patients with life-threatening conditions. RemeGen's main focus is research and development, manufacturing and commercialization of novel biologics, most notably monoclonal antibodies (mAb) and antibody-drug conjugates (ADCs). Headquartered in Yantai, Shandong Province, China, RemeGen has labs/offices in Beijing and California.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$100M
Remegen has raised a total of
$100M
in funding over 2 rounds. Their latest funding was raised on
Mar 17, 2020 from a Private Equity（PE） round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Mar 17, 2020 | Private Equity（PE） | $100M | 1 |
Lilly Asia Ventures
|
— | Detail |
| Dec 7, 2019 | Private Equity（PE） | — | 2 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
1
3
Remegen is funded by 3 investors.
Lilly Asia Ventures
and Huatai Health Fund
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Lilly Asia Ventures
|
Yes | Private Equity（PE） |
|
|
— | Private Equity（PE） |
Mingxin China Growth Fund
|
— | Private Equity（PE） |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
